Nurix Therapeutics to Present at the Stifel Healthcare Conference« back

SAN FRANCISCO, Nov 7, 2018 – Nurix Therapeutics, Inc., a private company discovering drugs that harness the body’s natural process to control protein levels, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, will present at the Stifel Healthcare on November 14, 2018 at the Lotte New York Palace hotel in New York City.

Presentation Details:

Presentation Title: Nurix Corporate Overview
Date: Wednesday, November 14, 2018
Time: 8:45 a.m. ET

About Nurix Therapeutics

Nurix discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our initial focus is on developing drugs as treatments for hematologic cancers and immune-mediated diseases including immuno-oncology therapeutics for cancer. Nurix was founded by internationally-recognized experts in ligase biology and immunology and is funded by leading life science investors Third Rock Ventures and The Column Group. In September 2015, Nurix and Celgene entered into a broad collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology. The company is headquartered in San Francisco, California. For more information, please visit

Media Contact

Sara Zelkovic
LifeSci Public Relations